



SUPRIYA LIFESCIENCE LTD.

Creating true values that bind global health

Date: January 21, 2022

To,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001
Scrip Code: 543434

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: SUPRIYA

Dear Sir (s),

Sub: Outcome of Board Meeting in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors of Company at its meeting held on January 21, 2022, has, inter alia, considered and approved the Unaudited Financial Results of the for the Quarter and nine months ended December 31, 2021 along with the Limited Review Report.

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (Listing Regulations), we are enclosing a copy of the above mentioned Unaudited Financial Results along with the Limited Review Report of the Auditors.


The Financials Results will be published in newspapers as required under the Listing Regulations.

The Meeting of the Board of Directors of the Company commenced at 11.30 a.m. and concluded at 12.25 p.m.

Kindly take the above said information on your records.

Thanking you,

Yours faithfully,
For Supriya Lifescience Limited


Shweta Singh

Company Secretary & Compliance Officer
Membership No.: A44973



Corporate Office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai 400 063. Maharashtra, India.

Tel : +91 22 40332727 / 66942507 | Fax : +91 22 26860011

CIN: U51900MH2008PLC180452 | E-mail: supriya@supriyalifescience.com | Website: www.supriyalifescience.com

Factory

: A-5/2, Lote Parshuram Industrial Area, M.I.D.C., Tal.-Khed, Dist.-Ratnagiri, Pin: 415 722, Maharashtra, India.

Tel: +91 2356 272299 | Fax : +91 2356 272178 | E-Mail: factory@supriyalifescience.com

GOVT. RECOGNISED EXPORT HOUSE

SUPRIYA LIFESCIENCE LIMITED
 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063. CIN: U51900MH2008PLC180452
 Tel No.: +91 22 40332727; E-mail: supriya@supriyalifescience.com; Website: www.supriyalifescience.com
 UNAUDITED FINANCIAL RESULTS

FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2021

Rs. in Millions, except per share data

Part I - Statement of Standalone Unaudited Financial Results for the Quarter & Nine Months Ended 31st December, 2021

Sr.No.	Particulars	Quarter ended	Quarter ended	Quarter ended	Nine Months	Nine Months Ended	Year ended
		31-12-2021	30-09-2021	31-12-2020	Ended	31-12-2020	31-03-2021
		Unaudited*	Unaudited*	Unaudited*	Unaudited*	Unaudited*	Audited*
	Income						
I	Revenue from Operations	1,170.00	1,480.06	806.91	3,418.00	2,557.17	3,853.66
II	Other Income	54.42	31.73	43.29	107.02	106.01	108.56
III	Total Income	1,224.41	1,511.80	850.20	3,525.02	2,663.18	3,962.21
2	Expenses						
	a) Cost of Materials Consumed	722.27	464.36	421.98	1,605.88	990.75	1,405.71
	b) Purchase of Stock in Trade	-	-	-	-	-	-
	c) Change in inventories of finished goods, work in progress & stock in trade.	-304.35	-28.22	-94.43	-356.15	-6.67	-124.45
	d. Employee benefit expenses	184.29	94.04	107.64	362.09	234.72	327.61
	e. Finance Cost	11.49	10.58	8.14	31.81	65.44	40.80
	f. Depreciation & amortisation expense	25.99	24.63	47.91	75.39	49.77	67.61
	g. Other expenditure	184.03	168.87	113.43	488.36	312.49	571.83
IV	Total Expenses	823.72	734.26	604.67	2,207.37	1,646.51	2,289.11
V	Profit/(loss) before Exceptional Items & Tax (III -IV)	400.70	777.54	245.53	1,317.65	1,016.67	1,673.10
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(loss) before Tax (V-VI)	-	-	-	-	-	-
VIII	Tax Expense						
	a) Current Tax	124.16	197.23	85.12	337.44	255.37	430.22
	b) Deferred Tax	-119.86	-1.90	3.48	-75.79	10.44	6.94
IX	Profit/(Loss) for the period from Continuing Operations (VII-VII)	396.40	582.20	156.93	1,055.99	750.86	1,235.93
X	Profit/(Loss) from discontinued operations before tax	-	-	-	-	-	-
XI	Tax Expense of discontinued operations	-	-	-	-	-	-
XII	Profit/(Loss) from discontinued operations after tax (X-XI)	-	-	-	-	-	-
XIII	Profit/(Loss) for the period (IX+XII)	396.40	582.20	156.93	1,055.99	750.86	1,235.93
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	-5.27	-0.56	-0.75	-5.77	-2.25	-1.66
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	1.33	0.14	0.19	1.45	0.57	0.42
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV)	-3.94	-0.42	-0.56	-4.32	-1.68	-1.24
XVI	Earnings per equity Share (for continuing operation):						
	(1) Basic	4.93	7.96	2.14	13.12	10.26	16.89
	(2) Diluted	4.93	7.96	2.14	13.12	10.26	16.89
XVII	Earnings per equity Share (for discontinued operation):						
	(1) Basic	-	-	-	-	-	-
	(2) Diluted	-	-	-	-	-	-
XVIII	Earnings per equity Share (for discontinued & continuing operations):						
	(1) Basic	4.93	7.96	2.14	13.12	10.26	16.89
	(2) Diluted	4.93	7.96	2.14	13.12	10.26	16.89




1. The above Unaudited Standalone Financial Results of the company were reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meeting held on 21st of January 2022.
2. The above financial results have been prepared in accordance with the Companies (Indian accounting Standards) Rules, 2015 (Ind AS as amended), prescribed u/s 133 of the Companies Act, 2013 read with relevant rules issued thereunder.
3. The company has taken into account the possible impacts of COVID-19 in preparation of the above standalone financial results, including but not limited to its assessment of liquidity and going concern assumption, recoverable values of its financial and non-financial assets, impact on revenue and on cost budgets in respect of fixed price contracts, impact on leases and impact on effectiveness of its hedging relationships. The Company has considered internal and certain external sources of information including reliable credit reports, economic forecasts and industry reports up to the date of approval of above standalone financial results and expects to recover the carrying amount of its assets. The impact of COVID-19 on the standalone financial results may differ from that estimated as at the date of approval of the standalone financial results.
4. Figures for previous periods have been regrouped / reclassified wherever considered necessary.

For Supriya Lifescience Limited



Satish Wagh
Chairman & Managing Director



Date: January 21, 2022

Place: Mumbai

KAKARIA AND ASSOCIATES LLP

CHARTERED ACCOUNTANTS

UJWAL K. KAKARIA B.Com., B.L., F.C.A.

SUBHASH S. KOTADIA B.Com. (HONS.) F.C.A.

JAIPRAKASH H. SHETHIYA B.Com., F.C.A.

YOUR REF.:

OUR REF.:

Independent Auditor's Review Report on Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To

The Board of Directors of Supriya Lifescience Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Supriya Lifescience Limited** ("the Company") for the Quarter ended 31st December, 2021 and the year-to-date results for the period 1st April 2021 to 31st December 2021, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended), including relevant circulars issued by SEBI from time to time.

2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been compiled from the related standalone IND AS Financial Statements which has been prepared in accordance with Indian Accounting Standards prescribed under Section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. The comparative financial information of the Company for the quarter and nine months ended December 31, 2021 prepared in accordance with Ind AS included in this Statement have been furnished to us by the Management which is neither audited or reviewed by us.

7. During quarter ended December 31. 2021. the Company has completed initial public offer (IPO) of 25547445 equity shares of face value of INR 2 each at an issue price of INR 274 per share, comprising fresh issue of 7299270 shares and offer for sale of 18248175 by Satish Waman Wagh.

802, Lotus Trade Centre, Near D.N. Nagar Metro Station, New Link Road, Andheri - West,

Mumbai - 400 053 Tele/Fax: 022 26744674/70. Email: mumbai@kakariaassociates.com,

Website: www.kakariaassociates.com

Pursuant to the IPO. The equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on December 28, 2021.

The Company has received an amount of INR 2000 million (net off IPO expenses of INR 1882.52 million) from proceeds out of fresh issue of equity shares. The utilisation of the net IPO proceeds is summarised below:

**(Amount in
Million)**

Objects of the Issue of Prospectus	Amount to be Utilized as per Prospectus	Utilization up to December 31,2021	Unutilized Amount as on December 31,2021
Funding capital expenditure requirements of our Company	923.00	0	923.00
Repayment and/or pre-payment, in full or part, of certain borrowings availed by our Company	600.00	0	600.00
General corporate purposes	359.52	100.00	259.52
Total	1,882.52	100.00	1782.52

For Kakaria and Associates LLP
Chartered Accountants
FRN: 104558W/ W100601

UJWAL
KANAIYALA
L. KAKARIA

Ujwal Kakaria
Partner
Membership No: - 035416
UDIN: 22035416AAAAAN6373

Date: 21.01.2022
Place: Mumbai